A champion of exploring new frontiers who brings deep expertise in machine learning and computational technologies and extensive experience in company formation, drug discovery and development.
Rosana Kapeller is co-founder, president and CEO of ROME Therapeutics, integrating her experience over 25 rewarding years as a scientific leader and company creator. As the founding Chief Scientific Officer of Nimbus Therapeutics, she led the company’s application of advanced computational technologies to the design and development of novel therapeutics. Most notably, Rosana led the discovery and development of a new class of Acetyl Co-A carboxylase (ACC) allosteric inhibitors for the treatment of NASH and other disorders, acquired by Gilead Sciences in a blockbuster deal in 2016. Before joining Nimbus, Rosana was a co-founder and VP of research at Aileron Therapeutics, where she led the development of the first stapled peptide drug candidate and was co-author on all major Aileron patents. Prior to ROME, she was an entrepreneur-in-residence at GV, where she is currently a Life Sciences Fellow. Across her entire career, Rosana has raised more than $250 million in venture capital funding and mentored many of today’s industry leaders. She has consulted for Third Rock Ventures and Atlas Venture, is a member of the board of directors of Schrödinger and Cedilla Therapeutics and sits on the key advisory board for the Blavatnik Fellowship in Life Science Entrepreneurship at Harvard Business School. Recognitions Rosana has received include selection for the Forbes 50 Over 50 Entrepreneurs list (2022), the Endpoints Women in Biopharma list (2019) and Fierce Pharma Fiercest Women in Life Sciences (2019). Rosana earned her M.D. from Universidade do Estado do Rio de Janeiro in Brazil and her Ph.D. in molecular and cellular biology from Tufts University.